Simulations Plus Sets Date for 1st Quarter 2016 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the first quarter of its 2016 fiscal year, ending November 30, 2015, with the U.S. Securities and Exchange Commission on Thursday, January 14, 2016. Dr. Ted Grasela, president, and Walt Woltosz, chairman and CEO, will host a conference call to discuss the Company’s performance on January 14, 2016, at 1:15 p.m. PST / 4:15 p.m. EST.
The conference call will be webcast live and may be joined by registering at the following website: https://attendee.gotowebinar.com/register/7532000268685717505. On registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (415) 930-5321, and enter access code 448-867-227.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.